John DiMatteo, MPH, RAC

Director, Molecule Development and Business Operations Princeton, New Jersey, USA john.dimatteo@covance.com

Key Roles and Responsibilities

- ► Formulates program-level development plan considerations across multiple contributing functional areas, from CMC through Health Authority Registration, consistent with goals of the Target Product Profile
- ► Formulates key go/no-go criteria and financial risk at appropriate program decision points
- Leads cross-functional teams in full or partial development of molecular entities
- Ensures operational feasibility of program strategy and monitors execution
- Mentors divisional Account Executives in crossfunctional client pipeline assessment

Areas of Expertise

- Operational Drug Development Team Leadership
- Assessing CRO capabilities across the development continuum and proposing novel solutions to client needs
- Assessing development plan risk and formulation of de-risking strategies
- Clinical Development strategies that best characterize the potential value of an asset at key decision points
- Drug Development
 - Nonclinical
 - Clinical
- Regulatory
- Commercialization

Professional Highlights

- ▶ More than 20 years of drug development experience at Johnson and Johnson, Hoechst (Aventis), Schering-Plough, Bristol-Myers Squibb and Forest Laboratories
- Led Project Teams in neuroscience indications and co-development activities
- Directed program and clinical project management teams
- Development of metrics and process improvement assessments of development stage gates
- Mr. DiMatteo joined Covance in 2013

Education

- ► BS, Biology

 City University of New York
- Master of Public Health (MPH)
 Walden University

Publication Journals

- Advances in Therapy
- ► International League Against Epilepsy (ILAE)

The Americas + 1.888.COVANCE + 1.609.452.4440 Europe/Africa + 00.800.2682.2682 Asia Pacific + 800.6568.3000



